Adjuvants for vaccines against respiratory syncytial virus

• US 5,723,130 A
• Filed: 09/16/1996
• Issued: 03/03/1998
• Est. Priority Date: 05/25/1993
• Status: Expired due to Fees

• Current Assignee: Wyeth Holdings Corporation (Pfizer Inc.)
• Original Assignee: American Cyanamid Co (Pfizer Inc.)
• Inventors: Hancock, Gerald E., Frenchick, Patrick J., Speelman, Dan J.
• Primary Examiner(s): Smith, Lynette F.
• Application Number:
  US08/553,332
• Time in Patent Office: 533 Days
• Field of Search: 424/211.1, 424/204.1, 424/184.1
• US Class Current: 424/211.1
• CPC Class Codes: A61K 2039/55572 Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• CPC Class Codes: A61K 2039/55577 Saponins; Quil A; QS21; ISCOMS
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61P 31/12 Antivirals

Abstract

Vaccine formulations and therapeutic methods therefor containing respiratory syncytial viral proteins or immunological fragment and an adjuvant selected from the group consisting of QS-21 3-deacylated monophosphoryl lipid A, monopohosphoryl lipid A and combination are described herein. Presence of the adjuvant(s) significantly increases the humoral and cell-mediated immunogenicity of the RSV proteins.

Claims

1. A vaccine formulation comprising (a) a respiratory syncytial viral (RSV) protein selected from the group consisting of (i) RSV glycoprotein G, (ii) RSV glycoprotein F, (iii) a chimeric glycoprotein consisting of the signal and extracellular domains of RSV glycoprotein F linked to the extracellular domain of RSV glycoprotein G, and (iv) combinations thereof, and (b) an adjuvant selected from the group consisting of QS-21, 3-deacylated monophosphoryl lipid A and combinations thereof, in a physiologically acceptable vehicle.

3. The vaccine formulation of claim 1 further comprising alum.

6. A method of protecting against lower respiratory disease and other disease symptoms of RSV infection in an individual comprising administering an effective amount of the vaccine of any one of claims 1, 2, 3, 4 or 5.

2. A vaccine formulation comprising (a) a respiratory syncytial viral (RSV) protein selected from the group consisting of (i) RSV glycoprotein G, (ii) RSV glycoprotein F, (iii) a chimeric glycoprotein consisting of the signal and extracellular domains of RSV glycoprotein F linked to the extracellular domain of RSV glycoprotein G, and (iv) combinations thereof, and (b) QS-21, in a physiologically acceptable vehicle.

4. The vaccine formulation of claim 2 further comprising alum.

5. A vaccine formulation comprising (a) a respiratory syncytial vital (RSV) protein selected from the group consisting of (i) RSV glycoprotein G, (ii) RSV glycoprotein F, (iii) a chimeric glycoprotein consisting of the signal and extracellular domains of RSV glycoprotein F linked to the extracellular domain of RSV glycoprotein G, and (iv) combinations thereof, and (b) alum and 3-deacylated monophosphoryl lipid A, in a physiologically acceptable vehicle.